

Vaccin'ERY™

New cancer immunotherapy based on *in situ* dendritic cells activation

Maud Bouvier, Business Development Manager, ERYtech Pharma

<p>Contact of the speaker Address :</p> <p>Phone: Email :</p>	<p>Maud BOUVIER Batiment Adenine 60, avenue Rockefeller 69008 LYON-FRANCE +33 (0)4 78 74 44 38 busdev@erytech.com</p>
<p>Executive Summary of the presentation</p>	<p>The innovative project GR-CAV1 deals with an attractive approach for cancer immunotherapy based on <i>in situ</i> dendritic cells activation thanks to the Vaccin'ERY™ system. This technology, patented by ERYtech Pharma, is very unique. It consists in using tumor antigens loaded red blood cells to specifically target <i>in situ</i> and activate immune cells to induce an anti-tumor response. Proof of preclinical concept will use a tumor cell lysate containing a broad array of tumor antigens and will be produced using Good Manufacturing Practice (GMP) guidelines. ERYtech Pharma aims to show efficacy of its immunotherapy strategy in both therapeutic and preventive approaches.</p> <p>ERYtech Pharma's technology of entrapment inside red blood cells is not limited by the size nor the nature of tumor antigens. Adjuvants can also be entrapped to target intracellular receptors making them much more effective. Product manufacturing requires only 2 hours thanks to an industrial process. This is a technical and an economic advantage which avoids complex and laborious manipulations of dendritic cells or macrophages, which are usually performed <i>ex vivo</i>. Thus using red blood cells loaded with an antigen may be a suitable alternative approach to target naturally and <i>in situ</i> the dendritic cells.</p>
<p>Actors and Partners (including international)</p>	<p>Dandrit Biotech Imaxio Innate Pharma UMR 5201 CNRS</p>
<p>Current Needs / Objectives (fund, partners, ...)</p>	<p>ERYtech Pharma is opened to co-development partnership with companies that are developing antigens and/or adjuvant in cancer vaccine.</p>